295 related articles for article (PubMed ID: 21392074)
21. The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.
Kim A; McCully C; Cruz R; Cole DE; Fox E; Balis FM; Widemann BC
Invest New Drugs; 2012 Apr; 30(2):524-8. PubMed ID: 21072558
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
23. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.
Djebli N; Rousseau A; Hoizey G; Rerolle JP; Toupance O; Le Meur Y; Marquet P
Clin Pharmacokinet; 2006; 45(11):1135-48. PubMed ID: 17048977
[TBL] [Abstract][Full Text] [Related]
24. Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.
Pawaskar DK; Straubinger RM; Fetterly GJ; Hylander BH; Repasky EA; Ma WW; Jusko WJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1219-29. PubMed ID: 23455451
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
Sugiyama M; Fujita K; Murayama N; Akiyama Y; Yamazaki H; Sasaki Y
Drug Metab Dispos; 2011 May; 39(5):757-62. PubMed ID: 21266595
[TBL] [Abstract][Full Text] [Related]
26. Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites.
Ghassabian S; Rawling T; Zhou F; Doddareddy MR; Tattam BN; Hibbs DE; Edwards RJ; Cui PH; Murray M
Biochem Pharmacol; 2012 Jul; 84(2):215-23. PubMed ID: 22513143
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib.
Rini BI
Expert Opin Pharmacother; 2006 Mar; 7(4):453-61. PubMed ID: 16503817
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
Pécuchet N; Lebbe C; Mir O; Billemont B; Blanchet B; Franck N; Viguier M; Coriat R; Tod M; Avril MF; Goldwasser F
Br J Cancer; 2012 Jul; 107(3):455-61. PubMed ID: 22767146
[TBL] [Abstract][Full Text] [Related]
29. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.
Lagas JS; van Waterschoot RA; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Mol Cancer Ther; 2010 Feb; 9(2):319-26. PubMed ID: 20103600
[TBL] [Abstract][Full Text] [Related]
30. Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.
Boudou-Rouquette P; Ropert S; Mir O; Coriat R; Billemont B; Tod M; Cabanes L; Franck N; Blanchet B; Goldwasser F
Oncologist; 2012; 17(9):1204-12. PubMed ID: 22752067
[TBL] [Abstract][Full Text] [Related]
31. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
Wei G; Wang M; Hyslop T; Wang Z; Carr BI
Int J Cancer; 2010 Dec; 127(12):2949-58. PubMed ID: 21351273
[TBL] [Abstract][Full Text] [Related]
32. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Okamoto I; Miyazaki M; Morinaga R; Kaneda H; Ueda S; Hasegawa Y; Satoh T; Kawada A; Fukuoka M; Fukino K; Tanigawa T; Nakagawa K
Invest New Drugs; 2010 Dec; 28(6):844-53. PubMed ID: 19760364
[TBL] [Abstract][Full Text] [Related]
33. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
34. A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.
Desar IM; Timmer-Bonte JN; Burger DM; van der Graaf WT; van Herpen CM
Br J Cancer; 2010 Nov; 103(11):1637-43. PubMed ID: 21045832
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis.
Hilger RA; Richly H; Grubert M; Kredtke S; Thyssen D; Eberhardt W; Hense J; Schuler M; Scheulen ME
Int J Clin Pharmacol Ther; 2009 Jan; 47(1):61-4. PubMed ID: 19203541
[No Abstract] [Full Text] [Related]
36. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
37. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
Mross K; Steinbild S; Baas F; Gmehling D; Radtke M; Voliotis D; Brendel E; Christensen O; Unger C
Eur J Cancer; 2007 Jan; 43(1):55-63. PubMed ID: 17095207
[TBL] [Abstract][Full Text] [Related]
38. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
39. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study.
Zhao JD; Liu J; Ren ZG; Gu K; Zhou ZH; Li WT; Chen Z; Xu ZY; Liu LM; Jiang GL
Radiat Oncol; 2010 Feb; 5():12. PubMed ID: 20149262
[TBL] [Abstract][Full Text] [Related]
40. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
Quintela-Fandino M; Le Tourneau C; Duran I; Chen EX; Wang L; Tsao M; Bandarchi-Chamkhaleh B; Pham NA; Do T; MacLean M; Nayyar R; Tusche MW; Metser U; Wright JJ; Mak TW; Siu LL
Mol Cancer Ther; 2010 Mar; 9(3):751-60. PubMed ID: 20197396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
